Eventide Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Eventide Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$448K	Buy	1,526 +415	+37%	+$125K	0.01%	242
2026 Q1	$351K	Sell	1,111 -32,924	-97%	-$11.2M	0.01%	238
2025 Q4	$13.5M	Sell	34,035 -67,704	-67%	-$30M	0.21%	122
2025 Q3	$46.4M	Sell	101,739 -24,163	-19%	-$9.84M	0.76%	44
2025 Q2	$41.1M	Sell	125,902 -40,548	-24%	-$11.2M	0.72%	44
2025 Q1	$44.9M	Sell	166,450 -73,968	-31%	-$19M	0.9%	38
2024 Q4	$56.6M	Buy	240,418 +16,085	+7%	+$4.23M	1.03%	30
2024 Q3	$61.7M	Buy	224,333 +137,333	+158%	+$35.8M	1.06%	32
2024 Q2	$21.1M	Hold	87,000	–	–	0.36%	88
2024 Q1	$13M	Hold	87,000	–	–	0.2%	111
2023 Q4	$16.7M	Buy	+87,000	New	+$14.8M	0.27%	96
2018 Q4	–	Sell	-62,000	Closed	-$5.43M	–	138
2018 Q3	$5.43M	Hold	62,000	–	–	0.2%	99
2018 Q2	$6.11M	Hold	62,000	–	–	0.25%	89
2018 Q1	$7.38M	Sell	62,000 -28,000	-31%	-$3.61M	0.35%	78
2017 Q4	$11.4M	Hold	90,000	–	–	0.6%	59
2017 Q3	$10.6M	Hold	90,000	–	–	0.6%	57
2017 Q2	$7.18M	Hold	90,000	–	–	0.45%	60
2017 Q1	$4.61M	Hold	90,000	–	–	0.31%	74
2016 Q4	$3.37M	Hold	90,000	–	–	0.22%	82
2016 Q3	$6.1M	Hold	90,000	–	–	0.37%	70
2016 Q2	$4.99M	Hold	90,000	–	–	0.31%	74
2016 Q1	$5.65M	Hold	90,000	–	–	0.32%	70
2015 Q4	$8.47M	Buy	90,000 +19,300	+27%	+$1.79M	0.42%	64
2015 Q3	$5.68M	Buy	70,700 +25,200	+55%	+$2.8M	0.33%	70
2015 Q2	$5.45M	Buy	45,500 +3,600	+9%	+$430K	0.3%	72
2015 Q1	$4.38M	Buy	+41,900	New	+$4.25M	0.33%	71

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eventide Asset Management's ALNY Position: Q2 2026 in Review

Eventide Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 37% in Q2 2026, buying an estimated $125K and bringing the position to 1,526 shares worth $448K. The position accounts for 0.01% of the portfolio, ranked #242.

Eventide Asset Management first reported a position in ALNY in Q1 2015 and has held it in 26 quarters since. The position peaked at $61.7M in Q3 2024. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Eventide Asset Management held 1,526 shares of Alnylam Pharmaceuticals worth $448K as of Q2 2026.
Eventide Asset Management bought 415 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $125K.
Alnylam Pharmaceuticals made up 0.01% of Eventide Asset Management's portfolio in Q2 2026, its #242 holding.
Eventide Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 26 quarters since.
Eventide Asset Management's Alnylam Pharmaceuticals position peaked at $61.7M in Q3 2024.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.